Sequent Scientific – Manish Gupta, MD

Sequent Scientific - Manish Gupta, MD – 12-04-2018

  • People confuse animal health to human pharma
  • Ours is a similar indutsry to FMCG
  • Animal health business is close to 900 crs on annual runrate basis
  • 70% revenue comes from europe; India is less than 10%
  • We are the only to have US FDA Approved Vet facility in the country
  • Aspiration is to be in global top 10 in next 4 years - Revenues of 2000 crs  (Current 800 odd crs)
  • Expecting improvement in margins of 200bps yoy - will be closer to 20% in next 4 years time
  • Growth will come from
    • Organic growth - as it is branded generic industry; every year we claw some shares of other
    • New product pipeline - 28 products under development
    • Inorganic strategies - for some of the unrepresented market in our portfolio
  • US and Australia are important veterinary geographies - Area of focus for inorganic growth
  • API - As we grow in US - Growth will be price driven and not volume driven - will translate into margins
  • We are focused on food producing animals (60% of global demand is in food producing animals)
  • With demerger of human API business, we now are pure play animal health company
  • Post demerger - effective debt is ~300 crs; have cash of 50 crs and investments in strides shares; net basis we are zero debt co.


Full Interview :

Leave a Reply

Your email address will not be published. Required fields are marked *